National Research Corp (NRC)

$32.87

-0.45

(-1.35%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on National Research Corp

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 36.16M → 38.00M (in $), with an average increase of 2.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, 6.64M → 8.85M (in $), with an average increase of 6.9% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 37.0% return, outperforming this stock by 61.0%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 12.5% return, outperforming this stock by 42.1%

Performance

  • $32.69
    $33.52
    $32.87
    downward going graph

    0.55%

    Downside

    Day's Volatility :2.48%

    Upside

    1.94%

    downward going graph
  • $32.87
    $46.43
    $32.87
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :29.21%

    Upside

    29.21%

    downward going graph

Returns

PeriodNational Research CorpSector (Health Care)Index (Russel 2000)
3 Months
-15.73%
-0.7%
0.0%
6 Months
-21.23%
6.6%
0.0%
1 Year
-24.0%
3.7%
-1.5%
3 Years
-29.32%
14.0%
-21.8%

Highlights

Market Capitalization
820.2M
Book Value
$2.02
Dividend Share
0.48
Dividend Yield
1.4%
Earnings Per Share (EPS)
1.25
PE Ratio
27.49
Profit Margin
20.84%
Operating Margin TTM
30.81%
Return On Assets TTM
19.81%
Return On Equity TTM
51.2%
Revenue TTM
148.6M
Revenue Per Share TTM
6.06
Quarterly Revenue Growth YOY
-0.4%
Gross Profit TTM
94.5M
EBITDA
46.0M
Diluted Eps TTM
1.25
Quarterly Earnings Growth YOY
0.34
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    37%Hold
    62%Sell
Based on 8 Wall street analysts offering stock ratings for National Research Corp(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
5
5
5

Company Financials

FY18Y/Y Change
Revenue
119.7M
↑ 1.81%
Net Income
30.0M
↑ 30.96%
Net Profit Margin
25.1%
↑ 5.58%
FY19Y/Y Change
Revenue
128.0M
↑ 6.93%
Net Income
32.4M
↑ 7.85%
Net Profit Margin
25.32%
↑ 0.22%
FY20Y/Y Change
Revenue
133.3M
↑ 4.14%
Net Income
37.3M
↑ 14.98%
Net Profit Margin
27.96%
↑ 2.64%
FY21Y/Y Change
Revenue
148.0M
↑ 11.01%
Net Income
37.5M
↑ 0.55%
Net Profit Margin
25.32%
↓ 2.64%
FY22Y/Y Change
Revenue
151.6M
↑ 2.44%
Net Income
31.8M
↓ 15.12%
Net Profit Margin
20.98%
↓ 4.34%
FY23Y/Y Change
Revenue
148.6M
↓ 1.97%
Net Income
31.0M
↓ 2.61%
Net Profit Margin
20.84%
↓ 0.14%
Q3 FY22Q/Q Change
Revenue
37.7M
↑ 1.07%
Net Income
8.3M
↓ 0.34%
Net Profit Margin
22.01%
↓ 0.31%
Q4 FY22Q/Q Change
Revenue
38.1M
↑ 1.2%
Net Income
6.6M
↓ 19.93%
Net Profit Margin
17.41%
↓ 4.6%
Q1 FY23Q/Q Change
Revenue
36.5M
↓ 4.38%
Net Income
7.0M
↑ 4.86%
Net Profit Margin
19.09%
↑ 1.68%
Q2 FY23Q/Q Change
Revenue
36.2M
↓ 0.86%
Net Income
7.3M
↑ 4.44%
Net Profit Margin
20.11%
↑ 1.02%
Q3 FY23Q/Q Change
Revenue
37.9M
↑ 4.93%
Net Income
7.9M
↑ 8.29%
Net Profit Margin
20.76%
↑ 0.65%
Q4 FY23Q/Q Change
Revenue
38.0M
↑ 0.15%
Net Income
8.9M
↑ 12.47%
Net Profit Margin
23.31%
↑ 2.55%
FY18Y/Y Change
Total Assets
107.7M
↓ 15.42%
Total Liabilities
88.6M
↑ 137.7%
FY19Y/Y Change
Total Assets
110.7M
↑ 2.79%
Total Liabilities
77.8M
↓ 12.2%
FY20Y/Y Change
Total Assets
133.4M
↑ 20.54%
Total Liabilities
69.1M
↓ 11.16%
FY21Y/Y Change
Total Assets
157.5M
↑ 18.08%
Total Liabilities
72.2M
↑ 4.48%
FY22Y/Y Change
Total Assets
130.5M
↓ 17.19%
Total Liabilities
58.4M
↓ 19.08%
FY23Y/Y Change
Total Assets
122.4M
↓ 6.15%
Total Liabilities
73.5M
↑ 25.77%
Q3 FY22Q/Q Change
Total Assets
135.0M
↓ 0.92%
Total Liabilities
67.2M
↓ 0.58%
Q4 FY22Q/Q Change
Total Assets
130.5M
↓ 3.35%
Total Liabilities
58.4M
↓ 13.08%
Q1 FY23Q/Q Change
Total Assets
134.3M
↑ 2.95%
Total Liabilities
59.6M
↑ 2.08%
Q2 FY23Q/Q Change
Total Assets
133.6M
↓ 0.51%
Total Liabilities
55.9M
↓ 6.31%
Q3 FY23Q/Q Change
Total Assets
120.1M
↓ 10.1%
Total Liabilities
62.3M
↑ 11.43%
Q4 FY23Q/Q Change
Total Assets
122.4M
↑ 1.92%
Total Liabilities
73.5M
↑ 18.02%
FY18Y/Y Change
Operating Cash Flow
39.8M
↑ 41.85%
Investing Cash Flow
-6.0M
↓ 2.4%
Financing Cash Flow
-54.5M
↑ 158.08%
FY19Y/Y Change
Operating Cash Flow
40.9M
↑ 2.68%
Investing Cash Flow
-4.7M
↓ 22.02%
Financing Cash Flow
-36.3M
↓ 33.31%
FY20Y/Y Change
Operating Cash Flow
40.6M
↓ 0.69%
Investing Cash Flow
-3.7M
↓ 20.02%
Financing Cash Flow
-15.5M
↓ 57.35%
FY21Y/Y Change
Operating Cash Flow
46.3M
↑ 14.05%
Investing Cash Flow
-8.5M
↑ 128.63%
Financing Cash Flow
-18.2M
↑ 17.15%
FY22Y/Y Change
Operating Cash Flow
36.3M
↓ 21.75%
Investing Cash Flow
-9.8M
↑ 15.52%
Financing Cash Flow
-55.6M
↑ 206.04%
Q3 FY22Q/Q Change
Operating Cash Flow
10.1M
↑ 2.33%
Investing Cash Flow
-4.0M
↑ 196.35%
Financing Cash Flow
-10.5M
↓ 53.88%
Q4 FY22Q/Q Change
Operating Cash Flow
8.1M
↓ 19.36%
Investing Cash Flow
-2.0M
↓ 50.64%
Financing Cash Flow
-9.5M
↓ 8.85%
Q1 FY23Q/Q Change
Operating Cash Flow
7.8M
↓ 4.33%
Investing Cash Flow
-3.2M
↑ 62.72%
Financing Cash Flow
-5.9M
↓ 38.65%
Q2 FY23Q/Q Change
Operating Cash Flow
8.8M
↑ 13.96%
Investing Cash Flow
-4.3M
↑ 35.64%
Financing Cash Flow
-5.7M
↓ 2.25%

Technicals Summary

Sell

Neutral

Buy

National Research Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
National Research Corp
National Research Corp
-16.22%
-21.23%
-24.0%
-29.32%
-14.54%
Solventum Corp
Solventum Corp
-10.64%
-10.64%
-10.64%
-10.64%
-10.64%
Veeva Systems Inc.
Veeva Systems Inc.
-12.8%
-3.39%
8.83%
-26.33%
55.83%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-5.98%
30.6%
1.83%
40.83%
40.83%
Healthequity Inc
Healthequity Inc
-3.72%
6.22%
37.05%
12.91%
23.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
National Research Corp
National Research Corp
27.49
27.49
NA
0.0
0.51
0.2
0.01
2.02
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
62.03
62.03
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.08
28.08
20.11
4.3
0.19
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
125.42
125.42
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
National Research Corp
National Research Corp
Sell
$820.2M
-14.54%
27.49
20.84%
Solventum Corp
Solventum Corp
NA
$11.7B
-10.64%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.3B
55.83%
62.03
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.0B
40.83%
28.08
8.02%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
23.47%
125.42
5.57%

Institutional Holdings

  • Kayne Anderson Rudnick Investment Management LLC

    12.08%

  • BlackRock Inc

    4.47%

  • Morgan Stanley - Brokerage Accounts

    3.96%

  • Vanguard Group Inc

    3.92%

  • Conestoga Capital Advisors, LLC

    3.27%

  • Dimensional Fund Advisors, Inc.

    2.67%

Corporate Announcements

  • National Research Corp Dividends March,2024

    In the quarter ending March,2024. National Research Corp has declared dividend of $0.12

    Read More

Company Information

nrc health (nasdaq:nrcia and nrcib) has helped healthcare organizations illuminate and improve the moments that matter to patients, residents, physicians, nurses, and staff for 35 years. our empathetic heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for, and in turn, design experiences that inspire loyalty and trust. for more information call 800-388-4264, write to info@nrchealth.com, or visit www.nrchealth.com.

Organization
National Research Corp
Employees
435
CEO
Mr. Michael D. Hays
Industry
Health Services

Discover More

FAQs